Hamrish Kumar Rajakumar’s Post

A persistent problem remains a challenge in HFpEF – patient heterogeneity. We need the right patients for the right treatment, but how do we get it to them? We believe one approach to solving this issue is to improve patient segregation and endotyping. In collaboration with BMS and UPenn, we have identified a subset of patients with very high risk of adverse outcomes, all identified by increased fibroblast activity. We can quantify this risk profile accurately using our PRO-C6 biomarker assay, separating patients according to how likely they are to experience re-hospitalization for HF or all-cause mortality. These findings were recently published in NEJM Evidence. So how do we go about handling patient heterogeneity? We believe the time is right to give doctors and clinicals a better tool at hand that what is available now. This is endotrophin endotyping, HF risk stratification redefined.   ▶️ You can find the article and more here: https://lnkd.in/ewUQDfGf #Endotrophin #PROC6 #heartfailure #drugdevelopment #cardiovascular #HFpEF Alexander Reese Federica Genovese Morten Asser Karsdal Mayuur Bajaj Daniel Gabor

Is there a risk for Baseline Lung Allograft Dysfunction (BLAD) in single lung transplant patients? The group of Michael Gerckens and Mümmler Carlo, #LHI (#HelmholtzMunich) and Ludwig Maximilian University Hospital (#LMU) has investigated this for the first time! The new findings ot their retrospective study have been published in "Transplantation". They highlight important risk factors for the condition, as well as its impact on patient survival rates after single lung transplants. 👉 https://lnkd.in/dfdhzwHp #LungScience #HelmholtzMunich #LungTransplant

Patient support programs (PSPs) can be so much better. Some are inefficient, wasting time and resources on interventions that wouldn’t ever be effective for certain individuals. Others struggle with low levels of engagement, failing to meet patients where they are. When a leading immunology biologic therapy manufacturer faced significant hurdles with its PSP, AllazoHealth helped consolidate data, streamline operations, and identify which patients needed interventions and when enabling a personalized experience. Click to learn more about our latest case study: https://ow.ly/kso750QrpW3 . . . #HealthcareAI #PatientSupportPrograms #MedicationAdherence #PatientEngagement #AIPersonalization

⚖️ Comparative Effectiveness Research in Action ⚖️ 💡 Making informed healthcare decisions is vital. Using German claims data, we can conduct comparative effectiveness research to evaluate different interventions and treatments. Let’s harness data to drive better health solutions! 💡 In a retrospective study using German claims data, we compared treatment outcomes in metastatic hormone-sensitive prostate cancer by replicating the CHAARTED trial. Patients meeting the inclusion/exclusion criteria of CHAARTED were identified and divided into two groups: those treated with docetaxel plus androgen deprivation therapy (ADT) and those treated with ADT monotherapy. After propensity score matching, the results closely matched the CHAARTED trial's results. This study highlights the value of real-world data in providing early comparative evidence for regulatory and health technology assessment decisions. Link to article: https://hubs.ly/Q02HMJwb0 #HealthcareResearch #ComparativeEffectiveness #RealWorldData #ProstateCancer #ClinicalTrials #HealthOutcomes #DataDrivenDecisions #MedicalResearch #HealthTech #Biostatistics #PharmaResearch #PatientOutcomes #EvidenceBasedMedicine #HealthcareInnovation

Managing anemia in lower-risk myelodysplastic neoplasms (MDS) is vital for patient care. In the latest edition of Oncolytics Today, Dr. Nikolaos Papadantonakis discusses the effectiveness of erythropoietin-stimulating agents and luspatercept, emphasizing the need for further research to explore treatment synergies and resistance mechanisms in MDS. Read more:  https://lnkd.in/euuUrFTS  #BloodCancerAwarenessMonth #CancerCare 

Sarcoma patients face significant challenges in diagnosis, often experiencing delays and misdiagnoses. While data highlighting these issues exist, there's a lack of comprehensive, internationally collated information about the sarcoma diagnosis pathway. This gap includes crucial factors like socio-demographics and external influences that affect diagnosis timing, accuracy, treatment decisions, and follow-up care, including referrals to specialized centers and genomic/mutational testing. To address this, #SPAGN’s Global Sarcoma Patient Survey aims to gather valuable data directly from sarcoma patients worldwide. By participating, you can make sure your real world experiences are heard and counted, and lead to improved diagnostic processes, better treatment options, and increased awareness of sarcoma symptoms. Your participation can make a difference in the lives of sarcoma patients everywhere. Early diagnosis saves lives! 💪💛 Ready to dive in? Click HERE to complete the survey! https://lnkd.in/dd64cmQD #SarcomaAwarenessMonth #SarcomaAwareness #SarcomaAwarenessMonth2024 #SAM2024 #SarcomaPatients #RareCancers #EarlyDiagnosisSavesLives #SPAGN

Register Today! Join Dr. Joseph Mikhael and Dr. Christopher Farnsworth during our next #webinar on September 18 at 12:00pm EDT! Dr. Joseph Mikhael will address the healthcare disparities that contribute to delayed Multiple Myeloma diagnoses and poor outcomes, emphasizing the importance of targeted screening for high-risk patients. Meanwhile, Dr. Farnsworth will present a comparative study of two serum free light chain assays that reveals the clinical specificity in diagnosing plasma cell disorders, particularly in patients with complex health conditions. --> Webinar: Timely Diagnosis of Myeloma in Populations with Comorbidities and Health Disparities: Testing Considerations 📆 September 18, 2024 🕛 12:00pm EDT ➡️ https://lnkd.in/euTpA_Tq #sebia #sebiausa #myeloma #Freelightchain #FLC #diagnosis #patientcare

Calling all Sarcoma Patients 💛💛 We know you face significant challenges in diagnosis, often experiencing delays and misdiagnoses. While data highlighting these issues exist, there's a lack of comprehensive, internationally collated information about the sarcoma diagnosis pathway. This gap includes crucial factors like socio-demographics and external influences that affect diagnosis timing, accuracy, treatment decisions, and follow-up care, including referrals to specialized centers and genomic/mutational testing. To address this, #SPAGN’s Global Sarcoma Patient Survey aims to gather valuable data directly from sarcoma patients worldwide. By participating, you can make sure your real-world experiences are heard and counted, and lead to improved diagnostic processes, better treatment options, and increased awareness of sarcoma symptoms. Your participation can make a difference in the lives of sarcoma patients everywhere. Early diagnosis saves lives! 💪💛 Click HERE to start the survey: https://lnkd.in/dd64cmQD #SarcomaAwareness #Campaigning4Cancer #SarcomaPatients #RareCancers #EarlyDiagnosisSavesLives #SPAGN

NICE - National Institute for Health and Care Excellence Institute for Health and Care Excellence Forward View 2024-2025 NICE has released their forward view for 2024-2025, outlining the key priority areas that will guide their efforts in the coming year. Their goal is to ensure that patients receive the most effective treatments promptly, while also delivering value to the taxpayer. These priorities are set to be reviewed and refreshed annually to stay responsive to significant developments and innovations in life sciences, health, and care. NICE’s Priority Areas: 🔹 Mental Health 🔹 Early Cancer Detection/Diagnosis 🔹 Diabetes 🔹 Musculoskeletal Conditions 🔹 Women’s Health 🔹 Respiratory 🔹 Neurology NICE’s horizon scanning function is actively evaluating emerging trends in health and care. Over the next 2-5 years, they anticipate reviewing new innovations in underserved clinical areas and exploring evolving delivery models to enhance existing treatments. They are particularly focused on new pharmacological treatments, advanced therapy medicinal products, and personalized medicine driven by high-throughput sequencing and AI. Do you need support to be compliant with the #UK, #European or #Swiss regulatory requirements for medical devices or #IVDs ? Reach out to us ☞ meetus@taoexcellence.ch #HealthcareExcellence #NICEGuidelines #HealthInnovation #StrategicPriorities #LifeSciences #FutureOfHealthCare #medtech #regulatoryaffairs #regulatorycompliance #invitrodiagnostics #clinicalaffairs #artificialintelligence #AI #publichealth #patientcare #healthtech

Another case study demonstrating the potential of German claims data! 📊 In this study, we replicated the CHAARTED trial, comparing treatment outcomes in metastatic hormone-sensitive prostate cancer. By using real-world data and propensity score matching, we achieved results closely matching those of the original trial. This highlights the power of using German claims for informed healthcare decisions. Feel free to reach out to find out more on how we can help you with your research!